***4D-710 ( Cystic Fibrosis) will be attached***
I need an Prior Art Search/IP Landscape conducted on 4D-710, the case 4D-710 will be attached as a resource
The following websites are to be used
USPTO - https://patft.uspto.gov/netahtml/PTO/search-bool.html
WIPO IP - https://patentscope.wipo.int/search/en/search.jsf
Free Patents Online https://www.freepatentsonline.com
***This is just a sample of a what is expected in the prior art search***
Prior Art Search/IP Landscape
Prior art search produced no known patents for the treatment of Stargardt Disease using drug therapy. The IP landscape was thoroughly searched against formal protections for a known drug therapy related to the treatment of Stargardt Disease. Formal patent protection for drug therapy related to the treatment of Stargardt Disease was searched using the following patent search engines: USPTO, WIPO IP, and Free Patents Online. The following terms were searched both exclusively and in tandem as to include all relevant information related to the IP landscape of the drug profile in question (NSR-ABCA4): Stargardt Disease, ABCA4, AAV, Viral Gene Therapy, CRISPR, Dual AAV Vector. There are currently less than 150 patents that mention both Stargardt Disease AND AAV gene therapy, however, there are exactly 0 other patents that report on drug therapy for the treatment of Stargardt Disease.
It should be noted that there does exist several patents that describe compositions and methods for the treatment of Stargardt Disease using viral gene therapy. According to the drug profile used for this assignment, “The gene therapy program utilizes a technology developed at Oxford University to target ABCA4 protein”. The following patents identify and describe this gene therapy and were discovered on Free Patents Online and PatentScope, respectively. Biogen is listed in concordance with the inventors at Oxford University as the holders of United States Patent Application XXXXXXXXXXidentifying a dual overlapping adeno-associated viral vector system for expressing ABCA4. In a separate patent holding WO XXXXXXXXXX, Nightstar (now owned by Biogen) in concordance with the inventors at Oxford University, describe the viral vector technology for gene therapy of Stargardt Disease aforementioned in the drug profile, NSR-ABCA4.